6.14
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Verastem Inc Borsa (VSTM) Ultime notizie
What drives Verastem Inc. stock priceUnstoppable profit momentum - PrintWeekIndia
FDA Grants Fast Track Designation to VS-7375 for KRAS G12D-Mutated Pancreatic Cancer - Targeted Oncology
Verastem Inc. Stock Analysis and ForecastRapid capital growth - PrintWeekIndia
Verastem Oncology Granted Fast Track Designation for VS-7375 for the Treatment of KRAS G12D-mutated Locally Advanced or Metastatic Pancreatic Cancer - BioSpace
What analysts say about Verastem Inc. stockFree Market Dynamics Reports - Autocar Professional
Is Verastem Inc. a good long term investmentAccelerated earnings growth - Autocar Professional
Verastem’s Phase 3 Study Update: A Potential Game-Changer in Ovarian Cancer Treatment - TipRanks
Verastem's Fast-Track KRAS G12D Inhibitor: A Strategic Play in a High-Unmet-Need Oncology Market - AInvest
Verastem Oncology gets FDA fast track status for cancer drug - Seeking Alpha
Verastem Oncology’s VS-7375 Granted Fast Track Designation by the FDA - Contract Pharma
FDA grants fast track designation to Verastem’s pancreatic cancer drug By Investing.com - Investing.com Canada
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - The Malaysian Reserve
High‑Growth Oncology Market Projected For US$900bn in Revenue Despite Policy Headwinds - Benzinga
(VSTM) Proactive Strategies - news.stocktradersdaily.com
Verastem’s Promising KRAS G12D Inhibitor Study: A Potential Game-Changer in Cancer Treatment - TipRanks
Verastem: The Market Is Ignoring The Progress (NASDAQ:VSTM) - Seeking Alpha
Why Verastem Inc. stock attracts strong analyst attentionDaily Trade Opportunity - beatles.ru
What makes Verastem Inc. stock price move sharplyEntry Level Low Risk Picks - Newser
How Verastem Inc. stock performs during market volatilityFast Moving Stock Alerts - Newser
Avutometinib-Defactinib: A New Standard in Precision Oncology? - AInvest
Verastem’s avutometinib combination shows 31% ORR in ovarian cancer trial - Yahoo Finance
Verastem Oncology's Breakthrough in LGSOC: A New Standard of Care with Substantial Upside Potential - AInvest
Verastem’s cancer drug shows 31% response rate in ovarian cancer trial By Investing.com - Investing.com Canada
Verastem stock rises after LGSOC treatment data published in medical journal - Investing.com
Verastem stock rises after LGSOC treatment data published in medical journal By Investing.com - Investing.com South Africa
Verastem Oncology Announces Publication of the Primary Results from the Phase 2 RAMP 201 Trial of Avutometinib in Combination with Defactinib in Patients with Recurrent Low-Grade Serous Ovarian Cancer in the Journal of Clinical Oncology - Yahoo Finance
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):